Health TRK Inhibitor Proves Beneficial in Primary CNS Tumors Jason Junior Jun 10, 2021 The TRK inhibitor larotrectinib (Vitrakvi) showed activity in patients with TRK fusion-positive primary central nervous system (CNS) tumors, according to an analysis of two trials.…
